xdemvy Drug Patent Profile

Which patents cover Xdemvy, and when can generic versions of Xdemvy launch?

Xdemvy is a drug marketed by Tarsus and is included in one NDA. There are nine patents protecting this drug.

The generic ingredient in XDEMVY is lotilaner. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the lotilaner profile page.

DrugPatentWatch^® Generic Entry Outlook for Xdemvy

Xdemvy will be eligible for patent challenges on July 24, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 14, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for xdemvy

US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Applications:	555
Drug Prices:	Drug price information for xdemvy
What excipients (inactive ingredients) are in xdemvy?	xdemvy excipients list
DailyMed Link:	xdemvy at DailyMed

See drug prices for xdemvy

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for xdemvy

NDA:

217603

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for xdemvy

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tarsus Pharmaceuticals, Inc.	Phase 4

See all xdemvy clinical trials

Pharmacology for xdemvy

Drug Class

Ectoparasiticide

US Patents and Regulatory Information for xdemvy

xdemvy is protected by nine US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes			Y
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes			Y
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes

EU/EMA Drug Approvals for xdemvy

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Elanco GmbH	Credelio	lotilaner	EMEA/V/C/004247For the treatment of flea and tick infestations.Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).DogsThis veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).CatsThis veterinary medicinal product provides immediate and persistent killing activity for 1 month against fleas (Ctenocephalides felis and C. canis) and ticks (Ixodes ricinus).	Authorised	no	no	no	2017-04-23

International Patents for xdemvy

When does loss-of-exclusivity occur for xdemvy?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering xdemvy around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018385766
Australia	2023200843
Australia	2025204628
Brazil	112020012018
Canada	3085787

Supplementary Protection Certificates for xdemvy

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379537	CR 2017 00034	Denmark		PRODUCT NAME: LOTILANER OG SALTE DERAF; REG. NO/DATE: EU/2/17/206/001-015 20170427
2379537	300891	Netherlands		PRODUCT NAME: LOTILANER EN ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/2/17/206 20170427
2379537	1790037-4	Sweden		PRODUCT NAME: LOTILANER AND SALTS THEREOF; REG. NO/DATE: EU/2/17/206 20170427
2379537	LUC00030	Luxembourg		PRODUCT NAME: LOTILANER ET SES SELS; AUTHORISATION NUMBER AND DATE: EU/2/17/206 20170427
2379537	17C0006	France		PRODUCT NAME: LOTILANER; REGISTRATION NO/DATE: EU/2/17/206 20170427

XDEMVY Market Dynamics, Sales Trajectory, Patent Protection, and Competitive Outlook

Last updated: September 19, 2026

XDEMVY, Tarsus Pharmaceuticals’ lotilaner ophthalmic solution 0.25%, is the first FDA-approved prescription treatment for Demodex blepharitis. Its commercial profile differs from conventional ophthalmic drugs because it created a branded category with no approved prescription substitute at launch. The principal market drivers are diagnosis rates, optometrist and ophthalmologist adoption, payer coverage, repeat treatment, and the conversion of symptomatic eyelid disease into a pharmacologically treated condition.

Tarsus has reported rapid post-launch growth, but XDEMVY remains exposed to several risks: limited historical awareness of Demodex blepharitis, dependence on one commercial product, reimbursement variability, off-label use of lower-cost alternatives, and eventual generic entry after regulatory and patent exclusivity expire.

What is XDEMVY and what market does it address?

XDEMVY contains lotilaner, an antiparasitic agent that targets Demodex mites. The FDA approved XDEMVY on July 25, 2023, for the treatment of Demodex blepharitis in adults and pediatric patients aged 6 years and older.[1]

Demodex blepharitis is associated with infestation of the eyelash follicles and meibomian glands by Demodex mites. Clinical signs include collarettes, eyelid inflammation, ocular irritation, redness, and dry-eye symptoms. Before XDEMVY, treatment commonly relied on lid hygiene, tea tree oil products, mechanical debridement, antibiotics, corticosteroids, or compounded therapies. Those approaches did not provide an FDA-approved drug specifically indicated for Demodex infestation.

The commercial opportunity is therefore based on both treatment substitution and market creation. Tarsus has marketed XDEMVY through eye-care professionals, including ophthalmologists and optometrists, rather than relying only on traditional pharmaceutical retail promotion.

FDA-approved dosage and treatment duration

The approved regimen is one drop in each affected eye twice daily for six weeks.[1] The six-week course supports a finite prescription model, although some patients may receive retreatment or remain candidates for additional management of chronic eyelid disease.

The principal clinical endpoints in the registration program included collarette reduction and mite eradication. The FDA label identifies common adverse reactions including instillation-site irritation and chalazion or hordeolum-related events.[1]

How large is the XDEMVY addressable market?

The addressable population is materially larger than the number of current prescriptions. Tarsus has cited a substantial prevalence of Demodex blepharitis among adults with blepharitis and dry-eye symptoms, but prevalence does not equal treated demand.

The market funnel has four stages:

1. Patients must present to an eye-care professional.
2. The clinician must recognize Demodex blepharitis.
3. The patient must receive a prescription rather than an over-the-counter or procedural treatment.
4. The prescription must be filled and completed.

The principal commercial constraint is diagnosis and treatment conversion. Many patients are managed for nonspecific blepharitis, meibomian gland dysfunction, or dry eye without a confirmed Demodex diagnosis. XDEMVY demand should rise as clinicians use collarettes as a diagnostic marker and adopt slit-lamp examination and mite-focused treatment protocols.

What is the financial trajectory for XDEMVY?

XDEMVY generated an accelerated launch curve after its July 2023 approval. Tarsus’ reported revenue growth reflects rapid prescription adoption from a low initial base, expansion of the prescribing network, and increased payer and pharmacy access.

Financial period	Commercial status	Main revenue driver
2023	Initial launch year	Early prescriptions and market education
2024	First full commercial year	Broader prescriber adoption, repeat demand, improved access
2025 onward	Expansion phase	Penetration of optometry, ophthalmology, and managed-care channels

Tarsus’ financial trajectory is highly concentrated in XDEMVY. That concentration creates operating leverage if prescriptions continue to expand, but it also magnifies execution risk. Sales and marketing expense, patient-support programs, payer contracting, and field-force expansion can reduce near-term profitability even while prescription volume grows.

The key financial indicators are:

• Gross-to-net deductions from rebates, discounts, co-pay support, and government programs.
• New prescription volume and total prescription volume.
• Refill and retreatment rates.
• Average net revenue per treated patient.
• Prescriber count and prescribing concentration.
• Payer coverage and prior-authorization requirements.
• Commercial sales and marketing expense as a percentage of revenue.
• Cash consumption before operating profitability.

XDEMVY has a favorable product characteristic for revenue planning: the therapy is administered as a defined six-week course rather than indefinitely. Revenue growth therefore depends on adding new treated patients, securing repeat courses, and expanding the diagnosed population.

When does XDEMVY lose exclusivity?

XDEMVY’s regulatory exclusivity and patent exclusivity are separate.

The FDA granted XDEMVY new chemical entity exclusivity. That five-year period is expected to run through July 2028, subject to the precise statutory calculation and any applicable regulatory extensions.[2] During this period, the FDA generally cannot approve an abbreviated new drug application that relies on the active ingredient’s full clinical safety and efficacy package.

The commercial protection may extend beyond 2028 through Orange Book-listed patents and other patents covering the formulation, ophthalmic delivery system, dosing regimen, or treatment method. The relevant end date depends on the specific listed patent and any patent-term adjustment or extension.

Protection type	Expected relevance
New chemical entity exclusivity	Blocks certain abbreviated approvals through approximately July 2028
Orange Book formulation or method patents	May delay approval or launch of an ANDA
Patent-term adjustment	Can extend an individual U.S. patent beyond its base term
Pediatric exclusivity	No separate six-month pediatric extension should be assumed without an FDA grant
Regulatory exclusivity outside the U.S.	Depends on national approval and data-exclusivity rules

A precise generic-entry date cannot be determined from FDA exclusivity alone. It requires review of the current Orange Book, patent listings, patent expiration dates, any pediatric extension, and litigation outcomes.

What patents protect XDEMVY?

The protection strategy is expected to rely on more than the lotilaner molecule. Lotilaner itself was previously developed as an antiparasitic compound, including in veterinary medicine. The commercially important human-drug barriers are therefore likely to include:

• The ophthalmic solution composition.
• Concentration and excipient selection.
• Delivery to the ocular surface and eyelid margin.
• Treatment of Demodex blepharitis with lotilaner.
• Dosing frequency and six-week treatment duration.
• Manufacturing and stability characteristics.

The FDA’s Orange Book is the controlling public source for patents listed against an approved drug product.[3] The most relevant claims for a generic challenger would likely be formulation and method-of-use claims rather than a broad claim to lotilaner as a chemical entity.

Patent strength is strongest where claims cover a clinically necessary formulation or a commercially unavoidable dosing method. Method-of-use patents can be more difficult to enforce than composition patents because an ANDA applicant may attempt a carve-out from the patented indication. Formulation patents can be stronger if the generic cannot reproduce the product’s stability, tolerability, or delivery profile without practicing the claimed subject matter.

What Paragraph IV challenges and generic entry risks exist?

No major public Paragraph IV litigation should be treated as established without a current review of FDA litigation records, court dockets, and Tarsus’ latest SEC filings. XDEMVY’s earliest serious ANDA challenge is more likely after the NCE exclusivity period approaches expiration, although a challenger can file earlier if it relies on a certification strategy permitted by the Hatch-Waxman framework.

A generic launch could occur through four principal scenarios:

Scenario	Commercial effect
No early challenge	Branded XDEMVY retains exclusivity until the first valid regulatory or patent barrier expires
Paragraph IV challenge with settlement	Entry date depends on the negotiated agreement
Successful Paragraph IV challenge	Generic could launch before listed patent expiry
At-risk launch	Generic enters before final patent resolution, exposing the challenger to damages and injunction risk

Because XDEMVY is a topical ophthalmic product, substitutability may depend on preservative systems, packaging, viscosity, drop size, sterility, and tolerability. An approved generic would still face clinician and payer acceptance issues, but pharmacy substitution and lower pricing could materially affect branded demand.

What is the Orange Book status of XDEMVY?

XDEMVY is an FDA-approved prescription drug listed under NDA 217343. The Orange Book should be used to confirm the current patent list, use codes, and any changes made after approval.[3]

The commercial importance of Orange Book listings is direct. A listed patent can trigger a 30-month stay if an ANDA applicant files a Paragraph IV certification and the NDA holder brings timely patent litigation. The stay does not guarantee ultimate patent validity or infringement, but it can delay FDA approval while litigation proceeds.

For investors and licensing parties, the relevant diligence questions are:

• Which patents are currently listed?
• Do the claims cover the drug product, formulation, or indication?
• What is the expiration date for each patent?
• Are use codes broad enough to capture the approved indication?
• Has an ANDA applicant filed a Paragraph IV certification?
• Has Tarsus initiated litigation?
• Has Tarsus entered a settlement agreement?

Which companies compete with XDEMVY?

XDEMVY has no FDA-approved prescription competitor with the same Demodex blepharitis indication. Its practical competitors are treatment alternatives rather than direct labeled substitutes.

Competitive categories

• Lid scrubs and hygiene products.
• Tea tree oil and terpinen-4-ol products.
• In-office lid debridement.
• Warm compresses and meibomian gland procedures.
• Topical antibiotics.
• Topical corticosteroids.
• Immunomodulatory dry-eye therapies.
• Compounded or off-label antiparasitic treatments.

The closest competitive threat is not a single branded drug. It is clinician inertia and the use of lower-cost supportive care. XDEMVY must demonstrate that targeted prescription treatment produces better outcomes, greater convenience, or more predictable control than repeated office procedures and nonprescription regimens.

How does XDEMVY compare with other ophthalmic drugs?

Attribute	XDEMVY	Conventional blepharitis treatment
FDA indication	Demodex blepharitis	Often nonspecific or off-label
Active mechanism	Antiparasitic against Demodex mites	Anti-inflammatory, antimicrobial, or mechanical
Treatment duration	Six weeks, twice daily	Variable and often chronic
Commercial status	Branded, single-product category	Fragmented alternatives
Generic competition	Not yet established	Present in several component categories
Diagnosis requirement	Demodex-focused diagnosis	Often symptom-based

XDEMVY’s differentiation is greatest when the clinician identifies mite-related disease rather than treating eyelid inflammation generically.

What licensing and manufacturing issues affect XDEMVY?

Tarsus obtained rights to lotilaner for human ophthalmic use through an agreement with Novartis. The commercial value of that arrangement depends on territorial rights, royalties, milestone obligations, sublicensing terms, and manufacturing responsibilities disclosed in the applicable SEC filings.

Manufacturing barriers are meaningful but unlikely to be insurmountable for a capable ophthalmic-generic manufacturer. Relevant technical requirements include sterile manufacturing, preservative control, container-closure integrity, drop uniformity, extractables and leachables testing, and stability throughout the labeled shelf life.

The stronger barrier is the combination of formulation know-how, regulatory experience, manufacturing validation, and patent risk. A generic competitor must overcome all four.

What is the outlook for XDEMVY revenue?

The base-case commercial outlook remains growth-oriented through the current market-development phase. Revenue expansion should come from:

• Increased Demodex diagnosis.
• More optometrists prescribing XDEMVY.
• Wider insurance coverage.
• Greater patient awareness.
• Repeat treatment for persistent or recurrent disease.
• Expansion of the treatment protocol across integrated eye-care networks.

The main downside risks are slower diagnosis conversion, payer restrictions, reduced adherence to the six-week course, lower-than-expected retreatment, and rapid adoption of compounded or procedural alternatives.

Tarsus’ revenue exposure is unusually concentrated because XDEMVY is its primary commercial product. A sustained decline in XDEMVY prescriptions would therefore affect corporate revenue, cash flow, valuation, and financing needs more directly than it would affect a diversified pharmaceutical company.

Key Takeaways

• XDEMVY is the first FDA-approved treatment specifically indicated for Demodex blepharitis.
• Its market is being created through diagnosis, clinician education, and conversion from nonspecific blepharitis care.
• FDA approval occurred on July 25, 2023.
• Five-year new chemical entity exclusivity is expected to protect the product through approximately July 2028.
• Patent protection may extend beyond regulatory exclusivity through formulation and method-of-use claims.
• No direct FDA-approved prescription competitor has been established in the same indication.
• The largest commercial competitors are lid hygiene, in-office procedures, off-label therapies, and compounded products.
• Tarsus’ financial exposure is concentrated in XDEMVY, making prescription growth and payer access central valuation variables.
• Generic-entry timing depends on Orange Book patents, Paragraph IV activity, litigation, and settlement terms.
• XDEMVY’s strongest commercial advantage is its disease-specific FDA label, not simply the lotilaner molecule.

FAQs

Is XDEMVY a biologic or a small-molecule drug?

XDEMVY is a small-molecule ophthalmic drug containing lotilaner. Biosimilar competition does not apply. Any future competition would generally involve generic-drug pathways rather than the abbreviated biosimilar pathway.

Can XDEMVY be used for ordinary blepharitis?

Its FDA approval is for Demodex blepharitis. Use for other forms of blepharitis would be outside the approved indication unless the patient also has Demodex-related disease.

Does XDEMVY require prior authorization?

Coverage varies by insurer and plan. Some payers may require prior authorization, step therapy, or documentation of Demodex blepharitis. Coverage terms can change independently of FDA approval.

Is lotilaner protected by patents outside the United States?

Protection varies by country and depends on national patent grants, supplementary protection mechanisms, regulatory exclusivity, and local litigation. U.S. Orange Book status does not establish protection in Europe, Japan, Canada, or other markets.

What would most increase XDEMVY’s long-term value?

The most important variables are durable clinician adoption, broader payer coverage, repeat-treatment demand, evidence supporting treatment of recurrent disease, and a patent or settlement outcome that delays generic entry beyond the initial regulatory exclusivity period.

References

1. U.S. Food and Drug Administration. (2023). XDEMVY (lotilaner ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (2023). XDEMVY approval letter, NDA 217343.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. Tarsus Pharmaceuticals, Inc. (2024). Form 10-K annual report. U.S. Securities and Exchange Commission.

DrugChatter Q&A for XDEMVY

Xdemvy lotilaner ophthalmic solution approved europe ema 2026?